



Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations

The Harvard community has made this
article openly available. [Please share](#) how
this access benefits you. Your story matters

Citation	Merkle, Florian T., Sulagna Ghosh, Nolan Kamitaki, Jana Mitchell, Yishai Avior, Curtis Mello, Seva Kashin, et al. 2017. "Human Pluripotent Stem Cells Recurrently Acquire and Expand Dominant Negative P53 Mutations." <i>Nature</i> (April 26). doi:10.1038/nature22312.
Published Version	doi:10.1038/nature22312
Citable link	http://nrs.harvard.edu/urn-3:HUL.InstRepos:33010384
Terms of Use	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

45 **Abstract**

46 **Background**

47 Depressive disorders are the second-leading cause of global disability, and an area of increasing
48 focus in international health efforts. We describe a community health worker (CHW) program
49 rolled out in a stepped-wedge design during the course of routine patient care to 74 patients with
50 depression in 4 communities in rural Mexico.

51
52 **Methods**

53 We used random effects models to calculate the change in Patient Health Questionnaire-9 (PHQ-
54 9) scores, an internationally validated measure of depression, before and after the CHW program
55 was introduced. As a secondary outcome, we also examined the change pre- and post-
56 intervention in the proportion of patients who had a mean of at least one visit per month for
57 depression follow-up, in accordance with clinic visit guidelines.

58
59 **Results**

60 In multivariate mixed-effects regression, the introduction of the CHW program was associated
61 with a 2.1-point decrease in PHQ-9 score (95% CI: -3.7 to -0.50) followed by a decrease in
62 PHQ-9 score of 0.19 points per month (95% CI: -0.41 to 0.02), beyond standard care. There was
63 strong evidence that patients were far more likely to attend a mean of at least one visit per month
64 (adjusted OR = 8.5, 95% CI: 7.2 to 9.7) after the intervention was introduced in a community.

66 **Conclusions**

67 Our results suggest an association between the introduction of a CHW program and improved
68 depression outcomes and appointment adherence. Our findings are limited by missing data.
69 Future research is necessary to develop evidence-based mental health interventions
70 implementable in low-resource settings.

71

72 **Keywords**

73 depression, CHW, community health, Mexico, LMIC

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95 **Background**

96 Depressive disorders are the second-leading cause of global disability, responsible for 3%
97 of disability-adjusted life years (DALYs) [1], and fewer than half of individuals suffering from
98 depression globally receive any kind of treatment [2]. As awareness of the burden of mental
99 health disorders in low- and middle-income countries (LMICs) has improved, there have been
100 increasing calls to incorporate mental health care into international priorities [3] and to develop
101 culturally-appropriate, scalable programs to address mental health problems in these regions [2].

102 Substantial evidence indicates that depression can be managed through anti-depressants
103 and behavioral interventions, but the majority of the literature comes from high-income countries
104 [4]. Studies from LMICs have generally found these interventions to be effective, but this body
105 of evidence is limited relative to that of high-income areas [4–8]. For example, a randomized-
106 controlled trial that evaluated a community-based depression intervention for low-income
107 women in Chile found strong evidence that community-based care significantly decreased
108 Hamilton depression rating scores, compared to those in traditional primary care [6]. Similarly, a
109 cluster-randomized group therapy intervention in Uganda reduced depression severity
110 significantly compared to controls [5]. However, such studies are relatively uncommon, limited
111 in scope, and have not fully explored how depression interventions can be effectively integrated
112 into routine care delivered through the primary health care system.

113 In Mexico, approximately 8% of the population experiences a major depressive episode
114 in his or her lifetime according to the Mexico National Comorbidities Survey [9]. Mental health
115 care is included as part of the essential package of cost-effective services included in Mexico's
116 national health insurance *Seguro Popular* [9–11]. Still, access is limited with only an estimated

117 15% of individuals with mood disorders receiving minimally adequate treatment [12]. We found
118 only one randomized-controlled trial from Mexico regarding depression, which focused on an
119 education intervention in an urban area, Mexico City, and demonstrated limited effectiveness [4].

120 One intervention that has been proposed as part of the development of mental health
121 services in LMICs is the provision of services by community health workers (CHWs). CHWs,
122 local community members trained to provide decentralized services and psychosocial support,
123 have played a key role in controlling infectious disease in developing countries, particularly HIV
124 [13–16]. They have also been effective in assisting patients with mental illness in the US [17].
125 However, there is little evidence on role of CHWs in treating non-communicable diseases in
126 resource-poor settings [18], and most evidence does not measure the effectiveness of CHWs to
127 treat mental health conditions within the context of routine primary care.

128 In this paper, we analyze a stepped-wedge roll-out of community health workers to treat
129 patients with depression in Chiapas, Mexico. We first describe the development and
130 implementation of a decentralized mental health intervention utilized in rural setting. We then
131 quantify the impact of the intervention, through measurement of PHQ-9 scores, a quantitative
132 measure of depression, and change in patient visit patterns before and after the intervention.

133 **Methods**

134 *Project background*

135 Chiapas is Mexico's southernmost state, bordering Guatemala. More than half of the
136 state's population lives below Mexico's poverty line [19], and the population has a high burden
137 of chronic illness [20].

138 In 2011, Partners In Health (PIH), an international non-profit, launched a sister
139 organization, Compañeros En Salud (CES), to support government-run health clinics in the

140 Sierra Madre region of Chiapas. In 2014, CES began an evaluation of the community health
141 worker program for patients with chronic illnesses in 4 communities. Primary data collection
142 only included patients with diabetes and hypertension, but routine illness data for all patients
143 who received a CHW was concurrently collected in CES's electronic medical record. This
144 article describes retrospective analysis based on depression data from electronic medical records.

145 *Program introduction & CHW recruitment*

146 The CHW program was rolled out in a stepped fashion approximately every 3 months
147 during one year (from March through December 2014), and the order in which communities
148 initiated the intervention was randomized (Figure 1). Each community held a public meeting to
149 propose the program's introduction, during which program activities were described, and
150 stakeholders had opportunities to share questions and concerns.

151 Following the initial meeting, nominations for CHWs were collected from community
152 members and staff from the health center. Nominees were required to be female, aged 18-60,
153 literate, and able to dedicate 5 hours per week to CHW duties. Following nomination, program
154 representatives interviewed and selected 1 CHW per approximately 6 patients with chronic
155 diseases.

156 *Staff structure and training*

157 CHWs received 32 hours of introductory training regarding the treatment of patients with
158 chronic illnesses, including diabetes, hypertension, epilepsy, depression, and asthma. Of these,
159 approximately 5 hours focused specifically on mental health topics including symptoms and
160 physiology of depression, side effects of antidepressant medications, and techniques for
161 communicating effectively with patients. Training emphasized role-play scenarios during which

162 CHWs could practice intervention techniques. Addition psychoeducation for CHWs was also
163 provided over the course of the intervention.

164 *Patient recruitment*

165 Patients were diagnosed with depression by a community physician if they reported
166 depressive symptoms for at least 2 weeks, as recorded in a PHQ-9 score or manually documented
167 in a chart, meeting DSM V criteria for depression. Approximately 7.9% of patients in CES's
168 catchment area met the formal criteria for depression [21]. All patients with depression who
169 lived in a community with CHWs were eligible to receive a CHW. Patients with depression
170 were offered a CHW when the program was introduced in their community, and after program
171 introduction, new patients were offered a community health worker following diagnosis. Those
172 who declined a CHW continued to receive standard care from the community physician.

173 *CHW visit techniques*

174 CHWs visited patients with depression once per week for 20-30 minutes, increasing or
175 decreasing the frequency of patient visits per an individual patient's needs. If a patient was not
176 home for a visit, the CHW returned until a patient became available. CHW support focused on 4
177 main tasks: encouraging patients to "name the problem"; providing hope that the illness was
178 treatable; identifying and encouraging tasks that could help patients manage their illness; and
179 mobilizing social support from friends and family.

180 *Patient follow-up and monitoring*

181 Patients with depression were also given monthly appointments with their community
182 physician, during which progress was noted and Patient Health Questionnaire 9 (PHQ-9) score
183 was documented in an electronic medical record. The PHQ-9 is designed to assist in the
184 diagnosis and management of patients with depression in primary care and has been previously

185 validated in a wide variety of patient populations, including the study population [22–25].
186 Patients with a PHQ-9 score higher than 15 were offered selective serotonin reuptake inhibitors
187 (SSRIs), either fluoxetine or sertraline.

188 ***Study design and population***

189 We performed a retrospective cohort study of all patients who were referred to the CHW
190 program for a diagnosis for depression between December 1, 2013, and June 31, 2015. We
191 conducted a review of patient’s medical charts to collect clinical and sociodemographic data
192 prior to and following the implementation of the community health worker intervention.

193 ***Outcome variables***

194 Our primary outcome was PHQ-9 score at routine visit, measured as a continuous
195 variable. A higher PHQ-9 score indicates poorer depression control, with scores greater than 5
196 indicating mild depression and score greater than 10 indicating moderate depression [26].

197 Our secondary outcome was frequency of patient visits to the community physician,
198 which were scheduled at least monthly. We analyzed this as a binary variable, by calculating the
199 mean number of visits per month for each patient over the enrollment period: 1) during the pre-
200 intervention period and 2) during the post-intervention period, and then created a variable equal
201 to 1 if the mean number of monthly visits was ≥ 1 and 0 otherwise. Though the number of
202 recommended visits per patient varied by disease severity, all patients should have received at
203 least one visit per month.

204 ***Predictor variables***

205 Individuals were considered exposed on the first day of program implementation in
206 his/her community. To estimate an interaction between the CHW intervention and time exposed

207 to the intervention, we calculated time since the initiation of the CHW intervention, measured in
208 months.

209 *Covariates*

210 We collected the following covariate data: age, sex, whether a patient had other chronic
211 illnesses in addition to depression that would render her eligible for a CHW, whether a patient
212 had ever been prescribed antidepressant medication, and time in months since a patient's
213 diagnosis with depression.

214 *Descriptive analyses*

215 In descriptive analyses, we tabulated demographic and baseline clinical statistics of
216 patients overall and in each community. We also calculated the percentage of visits missing a
217 PHQ-9 score, our primary outcome measure. We graphed patient trajectories, both overall and
218 by community, in order to visualize PHQ-9 score trends over time.

219 *Regression analyses*

220 We used linear mixed-effects regression to estimate patient PHQ-9 scores over time at
221 the visit-level, including random intercepts at the patient and community level. Our unadjusted
222 model included PHQ-9 score vs. time since intervention and time since diagnosis. We then
223 conducted a second adjusted analysis which included dummy variables for age groups, sex,
224 whether the patient had a prescription for anti-depressants, and whether the patient was
225 diagnosed with another chronic illness besides depression. We third added a term to consider the
226 possibility of different slopes in patient trajectory, a random slope associated with time since
227 intervention). For our secondary outcome, we used logistic mixed-effects regression to estimate
228 the odds ratios associated with attending a mean of at least 1 visit per month, with random
229 intercepts at the patient and community level. As we had a small sample size, we chose to use

230 restricted maximum likelihood for model estimation. We used AIC, which incorporates both
231 log-likelihood and number of parameters to provide a measure of model quality.

232 All analyses were conducted in R 3.1.2. Ethics approval was obtained from the Partners
233 Healthcare IRB (Protocol # 2015P001387/BWH).

234 **Results**

235 *Descriptive statistics*

236 Our sample contained 74 patients who attended 802 visits during the study period
237 (**Figure 2**). Mean patient age at first visit was 38, and 63 patients (85%) were female. Sixty-
238 three patients (85%) were prescribed antidepressants at some point during the study period.
239 Nearly a fifth of patients ($n = 14$, 19%) were diagnosed with at least one additional chronic
240 illness in addition to depression.

241 The mean baseline PHQ-9 score was 13.6, which indicates moderate to severe
242 depression. However, the baseline PHQ-9 score was only available at a patient's first visit in
243 43% of patients ($n = 32$); in the remaining patients, it was calculated based on the first measured
244 PHQ-9 score. Overall, 60% ($n=479/802$) of visits had PHQ-9 score data; not every visit required
245 a PHQ-9 score.

246 As the timing of the intervention was determined community level, we compared
247 communities based on demographic and baseline clinical variables. Though we observed some
248 heterogeneity between communities, they were similar in terms of most variables we measured,
249 including age at diagnosis, percentage female, and baseline PHQ-9 score. We did, however,
250 observe some differences. In particular, the percentage of patients with a chronic illness was
251 higher in Community A (44%, $n/N = 7/16$) than the sample average (19%, $n/N = 14/74$).

252

253 **Primary Outcome: PHQ-9 Score**

254 Overall, PHQ-9 score decreased over time (**Figure 3**). Results from primary analyses are
 255 displayed in **Table 1**. Our unadjusted model predicted PHQ-9 score decreased by 1.7 (95% CI: -
 256 3.3 to -0.08) points immediately following the intervention, and by 0.18 points each month
 257 thereafter (95% CI: -0.40 to -.04). After the minimum 9 months of follow-up, the model
 258 predicted a 3.3-point decrease in PHQ-9 score (95% CI: -5.7 to -0.96).

259
 260 **Table 1. Linear mixed effects regression of PHQ-9 score on CHW intervention.** Models #1 -
 261 #3 contain random intercepts by patient and community while model #3 also contains a random
 262 slope on time since intervention.
 263

Dependent variable:

	PHQ-9 score		
	(1) Unadjusted	(2) Adjusted	(3) Adjusted + RS
Intervention	-1.69** (-3.30, -0.08)	-2.09** (-3.68, -0.50)	-2.11** (-3.78, -0.43)
Time since intervention (months)	-0.18 (-0.40, 0.04)	-0.19* (-0.41, 0.02)	-0.22* (-0.45, 0.02)
Time since diagnosis (months)	-0.23*** (-0.40, -0.07)	-0.21*** (-0.37, -0.06)	-0.22*** (-0.38, -0.06)
Age 30-39		-1.05 (-3.86, 1.76)	-1.08 (-3.94, 1.78)
Age 40-49		-3.40** (-6.62, -0.19)	-3.74** (-7.00, -0.47)
Age 50+		-3.74** (-6.78, -0.69)	-3.85** (-7.00, -0.70)

Sex		-3.42** (-6.50, -0.33)	-2.98* (-6.20, 0.24)
Other chronic illness		-1.77 (-4.85, 1.31)	-1.15 (-4.30, 2.00)
On antidepressants		-3.18* (-6.68, 0.33)	-2.99* (-6.51, 0.53)
Constant	12.55*** (11.06, 14.05)	21.45*** (16.15, 26.74)	20.99*** (15.55, 26.43)

Observations	479	478	478
Log Likelihood	-1,528.91	-1,504.73	-1,503.04
Akaike Inf. Crit.	3,071.83	3,035.47	3,040.08
Bayesian Inf. Crit.	3,101.03	3,089.67	3,110.97

Note: *p<0.1; **p<0.05; ***p<0.01

264
265 In the adjusted model (2), the point estimate for the immediate effect of the intervention
266 was slightly larger (-2.1 points, 95% CI: -3.7 to -0.50), and the strength of the evidence for the
267 time since intervention effect remained similar (-0.19 points/month, 95% CI: -0.41 to 0.02).
268 After 9 months of follow-up, the model predicted a 3.8-point decrease in PHQ-9 score (95% CI:
269 -6.1 to -1.5).

270 In model (3), we added a random slope for on time since intervention to the adjusted
271 model. The point estimates for the intervention effects remained similar (-4.1 points after 9
272 months, 95% CI: -6.5 to -1.7).

273 The AIC for model (2) was substantially lower than the AIC for model (1), suggesting
 274 that adjusting for additional variables helped us to better explain the data. However, the AIC for
 275 models (2) and (3) were virtually identical, indicating similar fit.

276 ***Secondary Outcome: Mean Visits Per Month***

277 Results from our secondary analysis, which explored the change in mean number of visits
 278 per month before and after the intervention, are displayed in **Table 2**. In unadjusted analysis,
 279 there was strong evidence that the odds of having ≥ 1 visit per month on average were greater
 280 after the introduction of the intervention (OR: 7.8, 95% CI: 6.4 to 9.1). This effect larger in
 281 adjusted analysis, with an odds ratio of 8.5 (95% CI: 7.2 to 9.7) comparing the pre-intervention
 282 to post-intervention period.

283
 284 ***Table 2. Logistic mixed effects regression of mean visits per month on CHW intervention.***
 285 Both models contain random intercepts at the patient and community levels.
 286

Dependent variable:

	Binary: avg ≥ 1 visit/month (1) Unadjusted (2) Adjusted	
Intervention	7.76 ^{***} (6.44, 9.07)	8.47 ^{***} (7.23, 9.72)
Time since diagnosis (months)	0.99 ^{***} (0.88, 1.11)	0.97 ^{***} (0.86, 1.08)
Age 30-39		0.60 (-0.55, 1.76)
Age 40-49		0.97 (-0.32, 2.25)

Age 50+		0.87 (-0.33, 2.06)
Sex		1.51** (0.28, 2.74)
Other chronic illness		3.12*** (1.85, 4.39)
On antidepressants		6.93*** (5.46, 8.40)
Constant	0.45 (-0.35, 1.26)	0.06 (-2.35, 2.46)

Observations	140	139
Log Likelihood	-85.13	-77.49
Akaike Inf. Crit.	180.27	176.97
Bayesian Inf. Crit.	194.98	209.25

Note: *p<0.1; **p<0.05; ***p<0.01

287
288
289

Discussion

290 Our analysis of clinical data collected during a CHW intervention suggests the
291 intervention was associated with improved depression symptoms and more patient visits. During
292 the minimum 9-month post-intervention follow-up period, this translates to a 3.8 decrease in
293 PHQ-9 score beyond that which was achieved by standard care. PHQ-9 score has been found to
294 “broadly reflect” depression severity over time [23, 27], and a higher patient PHQ-9 score has
295 been correlated with negative health outcomes in this patient population [22]. In our model,
296 CHW effect size was larger in magnitude than the effect of being prescribed antidepressants, a

297 3.2-point decrease. It was also larger in size than effect of “time since diagnosis”, a variable
298 intended to capture the effect of routine care outside of CHW support, roughly a 3-point decline
299 over the average 15 months of time since diagnosis.

300 We further found that the mean number of patient visits per month increased following
301 the introduction of the CHW program, with the odds of a patient attending a mean of at least one
302 visit per month in the post-intervention period about 8 times higher than in the pre-intervention
303 period. This suggests that patients had more regular contact with physicians following the
304 intervention, possibly a result of CHWs improving adherence to clinical visits.

305 This study aims to address a dearth of literature describing culturally appropriate mental
306 health interventions that are implementable in low-resource settings [2]. The CHW program
307 described in this report relies on trained local community members to support facility-based care
308 provided by primary care physicians (PCPs). Some mental health interventions, such as the
309 WHO-CHOICE’s recommended “proactive collaborative care” in developing regions, aim to
310 support PCPs by including psychologists and psychiatrists in the provision of mental health care
311 in developing countries [11, 28, 29]. However, such interventions have rarely been tested in
312 resource-poor countries [28, 29], and relying on specialized mental health professionals is often
313 infeasible. For example, there are currently 26 psychiatrists in the state of Chiapas, which has a
314 population of 4.8 million [30]. Task-shifting to less specialized health professionals has been an
315 effective way to scale up treatment for other illnesses [31], and may assist in managing the
316 growing burden of depressive and mental illness.

317 Though we observed an association between the CHW program and our outcomes, we
318 are limited in our ability to draw casual claims about the relationship between the program and
319 patient depression. During the course of the CHW roll-out, there were ongoing efforts being

320 performed to improve the quality of care, both overall and targeted toward patients with
321 depression at CES. We were unable to quantify these factors in our analysis, but they may have
322 impacted PHQ-9 scores and trends and may have contributed to a greater number of patient visits
323 to the clinic. We cannot eliminate the possibility that other interventions accounted for all or
324 part of our observed treatment effect or for the interaction between treatment and time.
325 However, the stepped-wedge design helps to address secular trends: PHQ-9 score decreased
326 fairly quickly following the introduction of CHW programs at different times in different
327 communities.

328 Figure 3 also shows a wide variety of pathways patients took when working towards
329 clinical improvement. Such variability likely represents an important challenge, and opportunity,
330 for titrating CHW interventions to specific patient needs. This is especially true if these
331 fluctuations are related to social-economic conditions that peer-CHWs are arguably best
332 equipped to recognize and understand, such as crop failures or political turmoil.

333 We were also only able to measure the intervention at the community level rather than
334 the patient level. It is therefore possible that some patients were considered as having received
335 the intervention when they had not yet initiated; however, we suspect that this misclassification
336 would have attenuated the association between the intervention and our outcomes and therefore
337 is not a source of bias that could explain our findings. In addition, our work may not generalize
338 to all clinic populations. In particular, CES conducts door-to-door screening for depression in
339 their communities, which may result in diagnosis of depression and engagement in care of
340 patients who otherwise would not have sought care on their own. Finally, missing PHQ-9 score
341 data may bias our results. As not every visit required a PHQ-9 score, it was difficult to assess
342 potential effects of missing data.

343 Future work might explore which types of CHW-led interventions most improve
344 depression symptoms. Several mechanisms may have contributed to program effect including:
345 improved understanding of their disease (informational support), improved feelings of social
346 wellbeing and social connectedness with regular home visits (emotional support), increased
347 family intervention in the patient’s care, improved adherence to prescribed SSRIs (motivational
348 support), and improved patient activation for participation in psych-medical advice given
349 (instrumental support and peer-coaching). Future research can help delineate the relative
350 strength of these mechanisms in order to better design effective CHW-led interventions. It
351 would likewise be useful to compare different packages of depression interventions and quantify
352 the cost and value of these interventions.

353 **Conclusions**

354 Community health workers have been widely deployed to address a range of public
355 health problems and may be able to improve depression outcomes. Our study provides evidence
356 that a community-based depression program integrated into primary care in a rural setting was
357 associated with improved outcomes. Future research might more rigorously explore the
358 relationship between such programs and outcomes and the best way to deploy such programs.

359 **List of abbreviations**

360 CHW, community health worker; PHQ-9, Patient Health Questionnaire-9; DALY, disability
361 adjusted life years; LMIC, low- and middle-income countries; PIH, Partners In Health; CES,
362 Compañeros en Salud; SSRIs, selective serotonin reuptake inhibitors; PCPs, primary care
363 physicians
364

365 **Declarations**

- 366 • **Ethics:** Ethics approval was obtained from the Partners Healthcare IRB (Protocol #
367 2015P001387/BWH).
- 368 • **Consent for publication:** NA
- 369 • **Availability of data and material:** Data is available from CES for researchers who meet
370 requirements for working with patient records. Contact LPalazuelos@pih.org.
- 371 • **Competing interests:** The authors declare that they have no competing interests.

- 372 • **Funding:** Funding was provided by the London School of Hygiene and Tropical
373 Medicine Trust Funds (AB).
- 374 • **Authors' contributions:** AB, HC, MA, PN, PE, MF designed the study. AB, MF
375 conducted analyses. AB wrote the first draft. All authors edited the draft and approved
376 the final manuscript.
- 377 • **Acknowledgements:** NA
- 378 • **Authors' information (optional):** NA

379 **Figure Titles**

380 Figure 1. Study schematic. During control periods (grey), CHWs were not provided to chronic
381 disease patients; during intervention periods (black), they were provided.

382
383 Figure 2. Demographic and baseline clinical variables by community. The dashed grey line
384 indicates the overall inter-community mean for the variable. The black bars indicate the 95%
385 confidence interval for the variable.
386

387
388 Figure 3. Patient trajectories. The light purple dots and lines in the background indicate
389 trajectories of individual patients. The solid black line is the LOWESS smoother of all patient
390 trajectories, and the grey band surrounding it is the 95% confidence interval. The dotted purple
391 line indicates the date at which CHWs were introduced into a community.

392 **References**

- 394 1. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJL, et al. Burden of
395 Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of
396 Disease Study 2010. *PLoS Med.* 2013;10:e1001547.
- 397 2. mhGAP (Mental Health Gap Action Programme). Scaling up care for mental, neurological, and
398 substance use disorders. WHO; 2008.
399 http://www.who.int/mental_health/mhgap_final_english.pdf.
- 400 3. Thornicroft G, Patel V. Including mental health among the new sustainable development
401 goals. *BMJ.* 2014;349 aug20 5:g5189–g5189.
- 402 4. Patel V, Araya R, Chatterjee S, Chisholm D, Cohen A, De Silva M, et al. Treatment and
403 prevention of mental disorders in low-income and middle-income countries. *The Lancet.*
404 2007;370:991–1005.
- 405 5. Bolton P, Bass J, Neugebauer R, Verdelli H, Clougherty KF, Wickramaratne P, et al. Group
406 interpersonal psychotherapy for depression in rural Uganda: a randomized controlled trial.
407 *JAMA.* 2003;289:3117–24.
- 408 6. Araya R, Rojas G, Fritsch R, Gaete J, Rojas M, Simon G, et al. Treating depression in primary
409 care in low-income women in Santiago, Chile: a randomised controlled trial. *Lancet.*
410 2003;361:995–1000.

- 411 7. Lara MA, Navarro C, Navarrete L, Mondragón L, Rubí NA. Seguimiento a dos años de una
412 intervención psicoeducativa para mujeres con síntomas de depresión, en servicios de salud para
413 población abierta. *Salud Ment.* 2003;26:27.
- 414 8. Lara MA, Navarro C, Rubí NA, Mondragón L. Outcome results of two levels of intervention
415 in low-income women with depressive symptoms. *Am J Orthopsychiatry.* 2003;73:35–43.
- 416 9. Rafful C, Medina-Mora ME, Borges G, Benjet C, Orozco R. Depression, gender, and the
417 treatment gap in Mexico. *J Affect Disord.* 2012;138:165–9.
- 418 10. Ravindran TS. Universal access: making health systems work for women. *BMC Public*
419 *Health.* 2012;12 Suppl 1:S4.
- 420 11. Salomon JA, Carvalho N, Gutiérrez-Delgado C, Orozco R, Mancuso A, Hogan DR, et al.
421 Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost
422 effectiveness analysis. *BMJ.* 2012;344:e355.
- 423 12. Wang PS, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Borges G, Bromet EJ, et al. Use of
424 mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO
425 world mental health surveys. *The Lancet.* 2007;370:841–50.
- 426 13. Franke MF, Kaigamba F, Socci AR, Hakizamungu M, Patel A, Bagiruwigize E, et al.
427 Improved Retention Associated With Community-Based Accompaniment for Antiretroviral
428 Therapy Delivery in Rural Rwanda. *Clin Infect Dis.* 2013;56:1319–26.
- 429 14. Nacheга JB, Chaisson RE, Goliath R, Efron A, Chaudhary MA, Ram M, et al. Randomized
430 Controlled Trial of Trained Patient-Nominated Treatment Supporters Providing Partial Directly
431 Observed Antiretroviral Therapy. *AIDS Lond Engl.* 2010;24:1273–80.
- 432 15. Pearson CR, Micek MA, Simoni JM, Hoff PD, Matediana E, Martin DP, et al. Randomized
433 Control Trial of Peer-Delivered, Modified Directly Observed Therapy for HAART in
434 Mozambique. *J Acquir Immune Defic Syndr 1999.* 2007;46:238–44.
- 435 16. Herce ME, Kalanga N, Wroe EB, Keck JW, Chingoli F, Tengatenga L, et al. Excellent
436 clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated
437 with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi. *J Int AIDS*
438 *Soc.* 2015;18. doi:10.7448/IAS.18.1.19929.
- 439 17. Singh P, Sachs JD. 1 million community health workers in sub-Saharan Africa by 2015. *The*
440 *Lancet.* 2013;382:363–5.
- 441 18. Rahman A, Malik A, Sikander S, Roberts C, Creed F. Cognitive behaviour therapy-based
442 intervention by community health workers for mothers with depression and their infants in rural
443 Pakistan: a cluster-randomised controlled trial. *The Lancet.* 2008;372:902–9.
- 444 19. Investing in rural people in Mexico. International Fund for Agricultural Development; 2014.

- 445 20. Stevens G, Dias RH, Thomas KJA, Rivera JA, Carvalho N, Barquera S, et al. Characterizing
446 the Epidemiological Transition in Mexico: National and Subnational Burden of Diseases,
447 Injuries, and Risk Factors. *PLoS Med.* 2008;5:e125.
- 448 21. Elliott M, Aguerrebere M, Flores H, Palazuelos D, Elliott P. Depression in rural communities
449 and primary care clinics in Chiapas, Mexico. *Manuscr Prep.* 2015.
- 450 22. Arrieta J. Validation of the PHQ-9 in Chiapas, Mexico. *Manuscr Prep.* 2015.
- 451 23. Baas KD, Cramer AOJ, Koeter MWJ, van de Lisdonk EH, van Weert HC, Schene AH.
452 Measurement invariance with respect to ethnicity of the Patient Health Questionnaire-9 (PHQ-9).
453 *J Affect Disord.* 2011;129:229–35.
- 454 24. Monahan PO, Shacham E, Reece M, Kroenke K, Ong’or WO, Omollo O, et al.
455 Validity/Reliability of PHQ-9 and PHQ-2 Depression Scales Among Adults Living with
456 HIV/AIDS in Western Kenya. *J Gen Intern Med.* 2009;24:189–97.
- 457 25. Adewuya AO, Ola BA, Afolabi OO. Validity of the patient health questionnaire (PHQ-9) as
458 a screening tool for depression amongst Nigerian university students. *J Affect Disord.*
459 2006;96:89–93.
- 460 26. Arrieta J, Aguerrebere M, Raviola G, Flores H, Espinosa A, Reyes A, et al. Validity and
461 utility of the PHQ-2 and PHQ-9 for screening and diagnosis of depression in rural Chiapas,
462 Mexico. *J Clin Psychol.* In press.
- 463 27. Malpass A, Shaw A, Kessler D, Sharp D. Concordance between PHQ-9 scores and patients’
464 experiences of depression: a mixed methods study. *Br J Gen Pract.* 2010;60:e231–8.
- 465 28. Katon W, Von Korff M, Lin E, et al. Stepped collaborative care for primary care patients
466 with persistent symptoms of depression: A randomized trial. *Arch Gen Psychiatry.*
467 1999;56:1109–15.
- 468 29. Simon GE, Katon WJ, VonKorff M, Unützer J, Lin EH, Walker EA, et al. Cost-effectiveness
469 of a collaborative care program for primary care patients with persistent depression. *Am J*
470 *Psychiatry.* 2001;158:1638–44.
- 471 30. Heinze G, Carmen-Chapa G, Sastibeban J, Vargas I. Los especialistas en psiquiatría en
472 México: su distribución ejercicio profesional y certificación. *Salud Ment.* 2012;35:279–85.
- 473 31. Bemelmans M, Van Den Akker T, Ford N, Philips M, Zachariah R, Harries A, et al.
474 Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and
475 decentralization of HIV/AIDS care. *Trop Med Int Health.* 2010;15:1413–20.
- 476